Efficacy and safety of fezakinumab (an anti-IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments - A randomized, double-blind, phase 2a trial
scientific article published on 15 January 2018
Author/s
author: Patrick M Brunner, Emma Guttman-Yassky, James G. Krueger, Judilyn Fuentes-Duculan, Claudia Traidl-Hoffmann, Sandra Garcet, Yeriel D Estrada, Patricia M Gilleaudeau, Mary Sullivan-Whalen, Saakshi Khattri, Kunal Malik, Danielle Baum, Shelbi Jim On, Mark G. Lebwohl
Work details
Copyright status
Copyright status information is not available for this work. The copyright status depends on the jurisdiction, the author's date of death and the date the work was created or published.
To learn more about copyright terms in different countries, visit the countries and terms page.